Loading…
Cytosorbents Corporation is projected to rise to $0.3826 by 2027, a 0% move from its current price of $0.3813. CTSO is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $0.3621 | $0.3814 | $0.4017 | +0.03% |
| Jul 15 | $0.3545 | $0.3815 | $0.4106 | +0.06% |
| Jul 16 | $0.3488 | $0.3816 | $0.4175 | +0.09% |
| Jul 17 | $0.3441 | $0.3818 | $0.4235 | +0.12% |
| Jul 18 | $0.34 | $0.3819 | $0.4289 | +0.15% |
| Jul 19 | $0.3364 | $0.382 | $0.4338 | +0.18% |
| Jul 20 | $0.3331 | $0.3821 | $0.4384 | +0.21% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.3331 | $0.3821 | $0.4384 | +0.21% |
| Week 2 | $0.3153 | $0.3829 | $0.465 | +0.42% |
| Week 3 | $0.3025 | $0.3837 | $0.4868 | +0.63% |
| Week 4 | $0.2921 | $0.3845 | $0.5061 | +0.84% |
| Week 5 | $0.2834 | $0.3853 | $0.5238 | +1.05% |
| Week 6 | $0.2758 | $0.3861 | $0.5406 | +1.26% |
| Week 7 | $0.269 | $0.3869 | $0.5565 | +1.47% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform. Its flagship CytoSorb is an extracorporeal blood purification cartridge designed to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications. The company also develops DrugSorb-ATR antithrombotic removal system, ECOS-300CY to reduce cytokines and other inflammatory mediators in ex vivo organ perfusion, VetResQ for veterinary use, and PuriFi, an advanced hemoperfusion pump for blood purification therapies.
Cytosorbents was founded in 1997 and is headquartered in Princeton, New Jersey, and it was formerly known as MedaSorb Technologies Corporation, changing its name to Cytosorbents Corporation in May 2010.
Cytosorbents Corporation (CTSO) is a healthcare company trading in the stock market under the healthcare sector. It is currently priced at $0.39 per share with a market capitalization of $24.51M and a market rank of 4830. The stock operates in a small-cap segment with notable volatility implied by its 100% annualized volatility.
The near-term forecast suggests a flat to modestly improving path, while the multi-year outlook points to stronger bullish momentum and meaningful long-term upside, culminating in a 2050 average price near $1.74 and a potential max around $4.00 with substantial upside relative to today.
A major floor 30.9% below — a decisive break under it would weaken the trend.
The nearest floor, 5.1% below — buyers have tended to step in here.
The nearest ceiling, 36.1% above — a clean break opens room to run.
A major ceiling 112.4% above — clearing it would confirm fresh momentum.
Key CTSO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CTSO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.396 | Sell | $0.3877 | Sell |
| MA 10 | $0.3879 | Sell | $0.3967 | Sell |
| MA 20 | $0.4151 | Sell | $0.4146 | Sell |
| MA 50 | $0.4784 | Sell | $0.4703 | Sell |
| MA 100 | $0.5697 | Sell | $0.5422 | Sell |
| MA 200 | $0.6601 | Sell | $0.6474 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 42.29 | Neutral |
| Stoch RSI (14) | 44.16 | Neutral |
| CCI (20) | -68.64 | Neutral |
| Williams %R (14) | -81.90 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | -11.19 | Sell |
| Bollinger %B (20,2) | 0.29 | Neutral |
| Stochastic %K (14) | 18.10 | Buy |
| TRIX (15) | -0.82 | Sell |
| Awesome (5,34) | -0.04 | Sell |
| Ultimate (7,14,28) | 48.08 | Neutral |
| Momentum (10) | -0.08 | Sell |
| Aroon Osc (25) | -28.00 | Sell |
| Hull MA (9) | 0.38 | Sell |
| ADX (14) | 18.05 | Neutral |
| ATR (14) | 0.02 | Info |
The 30-day technical picture is Neutral, with RSI at 40 indicating neither oversold nor overbought conditions. The 50-day simple moving average sits at $0.4876 and the 200-day simple moving average at $0.6658, suggesting a price that remains near recent levels.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.362 | $0.3813 | $0.5131 | 0% | Neutral | |
| $0.2791 | $0.3826 | $0.5666 | 0% | Neutral | |
| $0.3307 | $0.4807 | $0.7577 | +26% | Bullish | |
| $0.3783 | $0.5782 | $0.9558 | +52% | Bullish | |
| $0.3287 | $0.5258 | $0.9042 | +38% | Bullish | |
| $0.3206 | $0.535 | $0.9517 | +40% | Bullish | |
| $0.2987 | $0.519 | $0.9515 | +36% | Bullish | |
| $0.2532 | $0.4574 | $0.8614 | +20% | Neutral | |
| $0.3081 | $0.5779 | $1.12 | +52% | Bullish | |
| $0.3817 | $0.7429 | $1.47 | +95% | Bullish | |
| $0.3267 | $0.726 | $1.57 | +90% | Bullish | |
| $0.7084 | $1.57 | $3.62 | +313% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.362 | $0.3813 | $0.4511 | +0.00% |
| August 2026 | $0.3133 | $0.3789 | $0.4769 | -0.62% |
| September 2026 | $0.3196 | $0.3918 | $0.5033 | +3.40% |
| October 2026 | $0.2975 | $0.3691 | $0.4821 | -5.81% |
| November 2026 | $0.2847 | $0.3568 | $0.4727 | -3.33% |
| December 2026 | $0.3022 | $0.3824 | $0.5131 | +7.17% |
Click any year to see its month-by-month CTSO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, CTSO could reach as high as $0.5131, with a base case around $0.3813 and support toward $0.362 — roughly 0% from $0.3813. Price action looks broadly range-bound.
Expect CTSO to range from $0.2791 to $0.5666 through 2027. The $0.3826 average target implies a 0% move from current prices. That is up 0% on the projected 2026 average. A consolidation phase looks the most probable path here.
The CTSO price prediction for 2028 points to an average of $0.4807 (low $0.3307, high $0.7577) — a potential gain of +26% on today's $0.3813. Momentum favours further upside here.
In 2029, CTSO is projected to trade between $0.3783 and $0.9558, averaging $0.5782 — a potential gain of +52% from today's $0.3813. That is up +20% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Cytosorbents Corporation's 2030 outlook centres on $0.5258, within a $0.3287 to $0.9042 range. That is -9% versus the projected 2029 average. That marks a +38% change versus current levels. Momentum favours further upside here.
By 2031, CTSO could reach as high as $0.9517, with a base case around $0.535 and support toward $0.3206 — roughly +40% from $0.3813. Buyers look set to stay in control over this stretch.
Expect CTSO to range from $0.2987 to $0.9515 through 2032. The $0.519 average target implies a +36% move from current prices. That is -3% versus the projected 2031 average. Momentum favours further upside here.
The CTSO price prediction for 2033 points to an average of $0.4574 (low $0.2532, high $0.8614) — a potential gain of +20% on today's $0.3813. A consolidation phase looks the most probable path here.
In 2034, CTSO is projected to trade between $0.3081 and $1.12, averaging $0.5779 — a potential gain of +52% from today's $0.3813. That is up +26% on the projected 2033 average. Momentum favours further upside here.
Cytosorbents Corporation's 2035 outlook centres on $0.7429, within a $0.3817 to $1.47 range. That is up +29% on the projected 2034 average. That marks a +95% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, CTSO could reach as high as $1.57, with a base case around $0.726 and support toward $0.3267 — roughly +90% from $0.3813. Momentum favours further upside here.
Expect CTSO to range from $0.7084 to $3.62 through 2050. The $1.57 average target implies a +313% move from current prices. That is up +117% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in CTSO today (≈ 2,622.606871 CTSO) could be worth
$4,128.29
+$3,128.29 (+313%) by 2050 · US Dollar
Based on the average projected CTSO price of $1.57 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CTSOwould be worth at today's price.
$1,000 invested in CTSO on Jul 10, 2025 (≈ 877.192993 CTSO) would be worth
$334.47
-$665.53 (-66.6%) today · 0.33× · US Dollar
Based on a CTSO entry price of $1.14 vs. today's $0.3813.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.39 | $977.69 | -2.2% |
| 1 month ago | $0.411 | $927.74 | -7.2% |
| 3 months ago | $0.61 | $625.08 | -37.5% |
| 6 months ago | $0.701 | $543.94 | -45.6% |
| 1 year ago | $1.14 | $334.47 | -66.6% |
| All time (5.0y) ago | $7.72 | $49.39 | -95.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CTSO forecast.
Our base-case forecast reaches $0.76 around 2050.
Implied market cap at $0.76: $47.76M
Looking further out, the forecast shows a gradual shift toward bullish sentiment beginning in the later years. The 2026 forecast has an average of $0.39 with a 0% ROI. From 2028 onward, the model projects stronger upside, with 2028 averaging $0.5149 and a 32% ROI, 2029 averaging $0.619 with 58.7% ROI, and 2030 averaging $0.5542 with 42.1% ROI.
The long arc remains bullish through 2040 and into 2050, with 2040 averaging $0.8047 and a 106.3% ROI, and 2050 averaging $1.74 with a 346.5% ROI (max $4.00). These figures imply meaningful long-term upside but are not guarantees and reflect a range of possible outcomes under varying market conditions. The forecast also notes higher volatility, underscoring the uncertainty inherent in long-term price projections.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $0.5542 per share, with a minimum of $0.3425 and a maximum of $0.962, and a projected ROI of 42.1%.
Yes. The forecast for 2031 shows a maximum of $1.02, with an average of $0.5683 and a ROI of 45.7%.
The forecast indicates bullish momentum from 2028 onward, with 2028 average $0.5149 and 2029 average $0.619 (ROI 32% and 58.7%, respectively), and long-term upside through 2050 (average $1.74, max $4.00, ROI 346.5%). These are estimates, not guarantees, and should be weighed against risks and market conditions.
The 2050 forecast lists a maximum price of $4.00, an average of $1.74, and a minimum of $0.7836, with a ROI of 346.5%.
Current price is $0.39 and market capitalization is $24.51M.
Cytosorbents Corporation Community Discussion
0Share your Cytosorbents Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.